A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma

Study Purpose

The main aims of this study are to test for any side effects from modakafusp alfa in combination therapy and to determine the recommended dose of combination therapy with modakafusp. The dose of modakafusp alfa will be increased a little at a time until the highest dose that does not cause harmful side effects is found. Participants will be given modakafusp alfa through a vein.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

1. Group 1 (MM maintenance: modakafusp alfa/lenalidomide) only must have: 1. MM based on standard IMWG diagnostic criteria. 2. Undergone ASCT for the treatment of MM within 12 months of the start of induction therapy and completed ASCT within 180 days before enrollment- (regardless of the lines of treatment).Consolidation cycles are allowed. Tandem transplant is allowed. 3. Not started lenalidomide maintenance before enrollment. Time to initiation of maintenance therapy: participants may start maintenance therapy as early as 60 days after transplantation and up to 180 days after transplantation or consolidation. 4. MRD positive ( after ASCT (MRD assessed at a threshold of 10^-5 by local SOC methods or central assessment, if a prior local MRD assessment had not been performed). 5. No prior progression after initial therapy (at any time before starting maintenance). Participants whose induction therapy was changed due to suboptimal response or toxicity will be eligible if they do not meet criteria for progression. In addition, no more than 2 regimens will be allowed before ASCT, excluding dexamethasone alone. 6. No prior allogeneic hematopoietic stem cell transplant or solid organ transplant. 7. Recovered to Grade less than or equal to (<=) 1 autologous stem cell transplant (ASCT) -related toxicities from the reversible effects of ASCT (except for alopecia and amenorrhea). ). MM based on standard IMWG diagnostic criteria. 2. Groups 2 and 3 (RRMM doublets and RRMM triplets) must have: 1. Measurable disease, defined as at least 1 of the following:
  • - Serum M-protein >=0.5 g/dL (>=5 g/L) on serum protein electrophoresis (SPEP).
  • - Urine M-protein >=200 mg/24 hours on urine protein electrophoresis (UPEP).
  • - Serum free light chain (FLC) assay result with an involved FLC level >=10 mg/dL (>=100 mg/L), provided the serum FLC ratio is abnormal (per IMWG criteria).
2. A confirmed diagnosis of MM according to IMWG criteria with documented disease progression in need of additional therapy as determined by the investigator. 3. For Group 2 RRMM doublet arms only: Participants who have received at least 3 prior lines of antimyeloma therapy, including at least 1 proteosome inhibitor (PI), 1 immunomodulatory drug (IMiD) and 1 anti-CD38 monoclonal antibody (mAb) drug, or who are triple refractory to a PI, and IMiD, and an anti-CD38 mAb drug regardless of the number of prior line(s) of therapy. d. For Group 3 RRMM triplet arms only: Participants who have received 1 to 3 prior lines of antimyeloma therapy including at least 1 PI and, 1 IMiD, and who are not refractory to the combination partners. e) For anti-CD38 arms, forced expiratory volume in 1second (FEV1) >=50% predicted by pulmonary function testing. 3. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 at screening. 4. Has adequate organ function at screening as determined by the laboratory values required for enrollment: Absolute neutrophil count (ANC) >=1000 per cubic millimeter (/mm^3) (or >=1*10^9/L); Platelets >=75,000/mm^3 (>=75*10^9/L); Hemoglobin >=8.0 g/dL; estimated creatinine clearance >=30 mL/min (Cockcroft-Gault formula); Total serum bilirubin <=2.0*Upper limit of normal (ULN); an exception for participants with Gilbert's syndrome may be granted after discussion with the sponsor; Liver transaminases (alanine aminotransferase [ALT])/aspartate aminotransferase [AST]) <=3.0*ULN. 5. Has recovered from adverse reactions to prior myeloma treatment or procedures (example, chemotherapy, immunotherapy, radiation therapy) to NCI CTCAE Version 5.0 Grade <=1 or baseline treatment or have the toxicity established as sequela, except for sensory or motor neuropathy, which should have recovered to Grade <=2 or baseline; ; (Grade 1 for the bortezomib arm).

Exclusion criteria:

1. Currently participating in another MM interventional study, including other clinical trials with investigational agents (including investigational vaccines or investigational medical device for disease under study) throughout the duration of this study. 2. Received previous treatment with modakafusp alfa. 3. Has a diagnosis of primary amyloidosis, Waldenström disease, monoclonal gammopathy of undetermined significance or smoldering MM per IMWG criteria or standard diagnostic criteria, plasma cell leukemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), lymphoplasmacytic lymphoma. 4. Has been diagnosed with another malignancy within the previous 3 years, except treated basal cell or localized squamous skin carcinomas, localized prostate cancer, cervical carcinoma in situ, resected colorectal adenomatous polyps, breast cancer in situ, or other malignancy for which the participant is not on active anticancer therapy and that in the opinion of the local investigator, with concurrence with the principal investigator, is considered cured with minimal risk of recurrence within 3 years. 5. Has evidence of CNS involvement and/or meningeal involvement due to MM exhibited during screening. 6. Has a known severe allergic or anaphylactic reactions to human recombinant proteins or excipients used in the modakafusp alfa formulation or to the study combination agents, the study medications, their analogs, or excipients in the various formulations of any agent per the prescribing information. 7. Is seropositive for hepatitis B (defined by a positive test for hepatitis B surface antigen [HBsAg]). Participants with resolved infection (that is, participants who are HBsAg negative but positive for antibodies to hepatitis B core antigen and/or antibodies to hepatitis B surface antigen [anti-HBs]) must be screened using real-time polymerase chain reaction (PCR) measurement of hepatitis B virus (HBV) DNA levels. Those who are PCR positive will be excluded. EXCEPTION: Participants with serologic findings suggestive of HBV vaccination (anti-HBs positivity as the only serologic marker) and, a known history of prior HBV vaccination do not need to be tested for HBV DNA by PCR. 8. Has a known history of seropositivity for HIV. 9. Has a known history of seropositivity for hepatitis C (anti-hepatitis C virus antibody positive or anti-hepatitis C virus-RNA quantitation positive). Exception: Participants with a sustained virologic response with undetectable HCV RNA level at least 12 weeks after completion of antiviral therapy. 10. For bortezomib arms: participants received a strong cytochromes P450 (CYP3A4) inducer within 5 half-lives prior to randomization. 11. The participant has a chronic condition requiring the use of systemic corticosteroids >10 mg/dL of prednisone or equivalent, in addition to any required corticosteroids for the treatment of MM. 12. Has a QTcF (QT interval corrected with Fridericia correction method >480 millisecond (ms) (Grade >=2).

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT05556616
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 1
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Takeda
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Study Director
Principal Investigator Affiliation Takeda
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Recruiting
Countries Austria, Belgium, Canada, Israel, Italy, Spain, Switzerland, United Kingdom, United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Multiple Myeloma
Study Website: View Trial Website
Additional Details

The drug being tested in this study is called modakafusp alfa (TAK-573). The study will evaluate the safety, tolerability and determine the recommended dose of modakafusp alfa in combination with lenalidomide in participants with multiple myeloma (MM), or in combination with pomalidomide, bortezomib, carfilzomib, or daratumumab in participants with relapsed/refractory multiple myeloma (RRMM). The study consists of 3 Groups: Group 1: MM Maintenance Therapy, Group 2: RRMM Doublets, Group 3: RRMM Triplets. The study will enroll approximately 18 participants in Group 1, 66 in Group 2, and 36 in Group 3. Participants will be assigned to one of the following treatment groups as given below:

  • - Group 1 (MM Maintenance) Arm 1: Modakafusp alfa + Lenalidomide.
  • - Group 2 (RRMM Doublets) Arm 2: Modakafusp alfa + Pomalidomide.
  • - Group 2 (RRMM Doublets) Arm 3: Modakafusp alfa + Bortezomib.
  • - Group 2 (RRMM Doublets) Arm 4: Modakafusp alfa + Carfilzomib.
  • - Group 3 RRMM Triplets) Arm A: Modakafusp alfa + Pomalidomide + Bortezomib.
  • - Group 3 (RRMM Triplets) Arm D: Modakafusp alfa + Daratumumab + Pomalidomide.
Group 2 Arm 4 is closed for enrollment. The study will be conducted worldwide. The maximum treatment duration in this study for Group 1 is until disease progression or unacceptable toxicity, or up to 2 years for minimal/measurable residual disease (MRD) negative [-] participants, whichever occurs first. The maximum treatment duration in this study for Group 2 and Group 3 is until disease progression, unacceptable toxicity or until any other discontinuation criterion is met, whichever occurs first. Overall time to participate in the study is approximately up to 5 years.

Arms & Interventions

Arms

Experimental: Group 1 (MM Maintenance) Arm 1: Modakafusp alfa + Lenalidomide

Modakafusp alfa, infusion intravenously (IV), once on Day 1, once every 4 weeks (Q4W), in combination with Lenalidomide capsules orally once daily continuously on Days 1 to 28, in a 28-day (4-week) treatment cycle until disease progression, unacceptable toxicity, or to a maximum of 2 years for MRD [-] negative participants, whichever occurs first. Participants who remain MRD positive with demonstrated clinical benefit after 2 years of maintenance therapy may continue treatment beyond 2 years with agreement of the sponsor/designee.

Experimental: Group 2 (RRMM Doublets) Arm 2: Modakafusp alfa + Pomalidomide

Modakafusp alfa, infusion IV, once on Day 1, Q4W in combination with Pomalidomide capsules orally once daily on Days 1 to 21 in a 28-day (4-week) treatment cycle until disease progression, unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first.

Experimental: Group 2 (RRMM Doublets) Arm 3: Modakafusp alfa + Bortezomib

Modakafusp alfa, infusion IV, once on Day 1, Q4W in combination with Bortezomib injection subcutaneously on Days 8, 15, and 22 for the first 8 cycles and subsequently on Days 8 and 22 of a 28-day (4-week) treatment cycle until disease progression, unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first.

Experimental: Group 2 (RRMM Doublets) Arm 4: Modakafusp alfa + Carfilzomib

Modakafusp alfa, infusion IV, once on Day 1, Q4W in combination with Carfilzomib IV, on Day 1, 8 and 15 of a 28-day (4-week) treatment cycle until disease progression, unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first. This arm is closed for enrollment after 3 participants were enrolled.

Experimental: Group 3 (RRMM Triplets) Arm A: Modakafusp alfa + Pomalidomide + Bortezomib

Modakafusp alfa, infusion IV, once on Day 1, Q4W in combination with Pomalidomide capsules orally once daily on Days 1 to 21 in a 28-day (4-week) treatment cycle along with Bortezomib injection subcutaneously on Days 8, 15 and 22 for the first 8 cycles and subsequently on Days 8 and 22 of a 28-day (4-week) treatment cycle until disease progression, unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first.

Experimental: Group 3 (RRMM Triplets) Arm D: Modakafusp alfa + Daratumumab + Pomalidomide

Modakafusp alfa, infusion IV, once on Day 1, Q4W in combination with Daratumumab injection subcutaneously on Days 1, 8, 15 and 22 of Cycles 1 and 2, further followed by on Days 1 and 15 of Cycles 3 to 6, thereafter on Day 1 on a 28-day (4-week) treatment cycle along with Pomalidomide capsules orally once daily on Days 1 to 21 in a 28-day (4-week) treatment cycle until disease progression, unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first.

Interventions

Drug: - Modakafusp alfa

Modakafusp alfa intravenous infusion.

Drug: - Lenalidomide

Lenalidomide capsules orally.

Drug: - Bortezomib

Bortezomib injection subcutaneously.

Drug: - Carfilzomib

Carfilzomib intravenous infusion.

Drug: - Daratumumab

Daratumumab injection subcutaneously.

Drug: - Pomalidomide

Pomalidomide capsules orally.

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Scottsdale, Arizona

Status

Not yet recruiting

Address

Hematology And Oncology Mayo Clinic Az, Mayo Clinic College Of Medicine

Scottsdale, Arizona, 85259

Site Contact

Site Contact

bergsagel.leif@mayo.edu

480-301-4704

Sacramento, California

Status

Recruiting

Address

University of California Davis Comprehensive Cancer Center

Sacramento, California, 95817

Site Contact

Site Contact

arosenberg@ucdavis.edu

916-734-5959

Scripps Health, San Diego, California

Status

Recruiting

Address

Scripps Health

San Diego, California, 92121

Site Contact

Site Contact

mahindra.anuj@scrippshealth.org

415-476-9000

USOR - Rocky Mountain Cancer Centers, Aurora, Colorado

Status

Not yet recruiting

Address

USOR - Rocky Mountain Cancer Centers

Aurora, Colorado, 80012

Site Contact

Site Contact

robert.rifkin@usoncology.com

303-388-4876

Aurora, Colorado

Status

Not yet recruiting

Address

University Of Colorado At Denver and Health Science Center

Aurora, Colorado, 80045

Iowa City, Iowa

Status

Active, not recruiting

Address

The University of Iowa Hospitals & Clinics

Iowa City, Iowa, 52242

Baltimore, Maryland

Status

Recruiting

Address

Cancer Center At Greater Baltimore Medical Center

Baltimore, Maryland, 21153

Site Contact

Site Contact

zli@gbmc.org

443-849-3051

Dana Farber Cancer Institute, Boston, Massachusetts

Status

Not yet recruiting

Address

Dana Farber Cancer Institute

Boston, Massachusetts, 02215

Site Contact

Site Contact

onadeem7@gmail.com

617-632-6140

Karmanos Cancer Institute, Detroit, Michigan

Status

Not yet recruiting

Address

Karmanos Cancer Institute

Detroit, Michigan, 48201

Site Contact

Site Contact

zonderj@karmanos.org

313-576-8673

Mayo Clinic, Rochester, Minnesota

Status

Not yet recruiting

Address

Mayo Clinic

Rochester, Minnesota, 55905

Site Contact

Site Contact

cook.joselle@mayo.edu

507-238-3828

Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada

Status

Recruiting

Address

Comprehensive Cancer Centers of Nevada

Las Vegas, Nevada, 89119

Site Contact

Site Contact

edwin.kingsley@usoncology.com

702-952-3400

NYU Langone Hospital - Long Island, Mineola, New York

Status

Recruiting

Address

NYU Langone Hospital - Long Island

Mineola, New York, 11501

Site Contact

Site Contact

faith.davies@nyulangone.org

929-455-2451

New York University School of Medicine, New York, New York

Status

Recruiting

Address

New York University School of Medicine

New York, New York, 10016

Site Contact

Site Contact

faith.davies@nyulangone.org

929-455-2451

New York, New York

Status

Active, not recruiting

Address

Weill Cornell Medicine/New York Presbyterian Hospital

New York, New York, 10021

Icahn School of Medicine at Mount Sinai, New York, New York

Status

Recruiting

Address

Icahn School of Medicine at Mount Sinai

New York, New York, 10029

Site Contact

Site Contact

larysa.sanchez@mssm.edu

212-241-6756

New York, New York

Status

Active, not recruiting

Address

Memorial Sloan Kettering Cancer Center - Main Campus

New York, New York, 10065

Novant Health Cancer Institute, Charlotte, North Carolina

Status

Active, not recruiting

Address

Novant Health Cancer Institute

Charlotte, North Carolina, 28204

Winston-Salem, North Carolina

Status

Active, not recruiting

Address

Novant Health Cancer Institute - Forsyth Medical Center

Winston-Salem, North Carolina, 27103

Gabrail Cancer Center Research, Canton, Ohio

Status

Recruiting

Address

Gabrail Cancer Center Research

Canton, Ohio, 44718

Oncology Hematology Care, Inc, Cincinnati, Ohio

Status

Not yet recruiting

Address

Oncology Hematology Care, Inc

Cincinnati, Ohio, 45236

Site Contact

Site Contact

Kruti.Patel@usoncology.com

+1-877-825-3327

Eugene, Oregon

Status

Not yet recruiting

Address

USOR - Willamette Valley Cancer Institute and Research Center

Eugene, Oregon, 97401

Site Contact

Site Contact

chris.yasenchak@usoncology.com

541-741-3451

Philadelphia, Pennsylvania

Status

Not yet recruiting

Address

University of Pennsylvania - Abramson Cancer Center

Philadelphia, Pennsylvania, 19104

Site Contact

Site Contact

dan.vogl@uphs.upenn.edu

215-615-6508

Texas Oncology, Dallas, Texas

Status

Not yet recruiting

Address

Texas Oncology

Dallas, Texas, 75246

Site Contact

Site Contact

moshe.levy@baylorhealth.edu

214-370-1000

Houston, Texas

Status

Recruiting

Address

The University of Texas MD Anderson Cancer Center

Houston, Texas, 77030

Site Contact

Site Contact

hclee@mdanderson.org

713-792-3510

Virginia Oncology Associates, Virginia Beach, Virginia

Status

Not yet recruiting

Address

Virginia Oncology Associates

Virginia Beach, Virginia, 23456

International Sites

Universitaetsklinikum St. Poelten, St. Poelten, Saint Poelten, Austria

Status

Not yet recruiting

Address

Universitaetsklinikum St. Poelten

St. Poelten, Saint Poelten, 3100

Ordensklinikum Linz GmbH Elisabethinen, Linz, Austria

Status

Not yet recruiting

Address

Ordensklinikum Linz GmbH Elisabethinen

Linz, , 5020

Salzburg, Austria

Status

Not yet recruiting

Address

Uniklinikum Salzburg, Landeskrankenhaus, Universitatsklinik fur Innere Medizin III der PMU

Salzburg, , 5020

Site Contact

Site Contact

r.greil@salk.at

435725525823

CHU UCL Namur site Godinne, Yvoir, Namur, Belgium

Status

Recruiting

Address

CHU UCL Namur site Godinne

Yvoir, Namur, 5530

Site Contact

Site Contact

julien.depaus@uclouvain.be

+3281422111

AZ Delta, Roeselare, Roeselare West-Vlaanderen, Belgium

Status

Recruiting

Address

AZ Delta

Roeselare, Roeselare West-Vlaanderen, 8800

Site Contact

Site Contact

dries.deeren@azdelta.be

+1-877-825-3327

University Hospitals Leuven, Leuven, Belgium

Status

Not yet recruiting

Address

University Hospitals Leuven

Leuven, , 3000

Site Contact

Site Contact

michel.delforge@uzleuven.be

3216346880

Liege, Belgium

Status

Not yet recruiting

Address

Centre Hospitalier Universitaire Sart Tilman

Liege, , 4000

Site Contact

Site Contact

jo.caers@chuliege.be

+32 43667704

Toronto, Ontario, Canada

Status

Not yet recruiting

Address

University Health Network (UHN) - Princess Margaret Cancer Centre - Myeloma Clinic

Toronto, Ontario, M5G 2M9

Site Contact

Site Contact

suzanne.trudel@uhn.ca

4169464501

Montreal, Quebec, Canada

Status

Not yet recruiting

Address

McGill University Health Centre (MUHC) - The Montreal General Hospital (MGH) - Cedars Cancer Centre

Montreal, Quebec, H4A 3JL

Site Contact

Site Contact

anna.nikonova@mcgill.ca

93419345718

Soroka University Medical Center (Sumc), Be'er Sheva, Beer Sheva Negev, Israel

Status

Not yet recruiting

Address

Soroka University Medical Center (Sumc)

Be'er Sheva, Beer Sheva Negev, 84101

Site Contact

Site Contact

rubio@bgu.ac.il

972544709242

Assuta Ashdod Medical Center, Ashdod, Israel

Status

Not yet recruiting

Address

Assuta Ashdod Medical Center

Ashdod, , 7747629

Site Contact

Site Contact

meravlei@assuta.co.il

+1-877-825-3327

Haifa, Israel

Status

Recruiting

Address

Rambam Health Care Campus (RHCC) - Meyer Children's Hospital - Pediatric Diabetes & Obesity Clinic

Haifa, , 31999

Site Contact

Site Contact

n_lavi@rambam.health.gov.il

502061332

Rabin Medical Center, Beilinson Campus, Petah Tikva, Israel

Status

Not yet recruiting

Address

Rabin Medical Center, Beilinson Campus

Petah Tikva, , 49100

Site Contact

Site Contact

juliava1@clalit.org.il

+1-877-825-3327

Brescia, Italy

Status

Not yet recruiting

Address

Azienda Ospedaliera Spedali Civili di Brescia-Universita degli Studi Di Brescia

Brescia, , 25123

Site Contact

Site Contact

ange.belotti@gmail.com

+1-877-825-3327

Meldola, Italy

Status

Not yet recruiting

Address

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS

Meldola, , 47014

Milan, Italy

Status

Not yet recruiting

Address

IRCCS-Istituto Europeo di Oncologia, Division di Oncoematologia

Milan, , 20141

Site Contact

Site Contact

enrico.derenzini@ieo.it

+1-877-825-3327

Azienda Ospedaliera Niguarda Ca' Granda, Milan, Italy

Status

Not yet recruiting

Address

Azienda Ospedaliera Niguarda Ca' Granda

Milan, , 20162

Napoli, Italy

Status

Not yet recruiting

Address

Universita degli Studi di Napoli Federico II

Napoli, , 80131

Site Contact

Site Contact

fabrizio.pane@unina.it

817462068

Ravenna, Italy

Status

Not yet recruiting

Address

Azienda Unita Sanitaria Locale di Ravenna - Ospedale S. Maria delle Croci di Ravenna

Ravenna, , 48121

Site Contact

Site Contact

c.cellini@ausl.ra.it

+1-877-825-3327

Rome, Italy

Status

Not yet recruiting

Address

Universita Cattolica del Sacro Cuore - Policlinico Universitario Agostino Gemelli, UOC Ematologia

Rome, , 168

Site Contact

Site Contact

valerio.destefano@unicatt.it

630154968

Barcelona, Catalunya, Spain

Status

Not yet recruiting

Address

Catalan Institute of Oncology (ICO) Hospitalet

Barcelona, Catalunya, 8907

Site Contact

Site Contact

asureda@iconcologia.net

935565649

Hospital Universitario de Canarias, Santa Cruz De Tenerife, Tenerife, Spain

Status

Not yet recruiting

Address

Hospital Universitario de Canarias

Santa Cruz De Tenerife, Tenerife, 38320

Site Contact

Site Contact

sunillakhwani@hotmail.com

922-678-000

Hospital De Cabuenes, Gijon, Spain

Status

Not yet recruiting

Address

Hospital De Cabuenes

Gijon, , 33394

Site Contact

Site Contact

esthergongar@yahoo.es

650915409

Madrid, Spain

Status

Not yet recruiting

Address

Clinica Universidad de Navarra-Sede Madrid

Madrid, , 28027

Site Contact

Site Contact

paurodriguez@unav.es

948-255-400

Malaga, Spain

Status

Recruiting

Address

Hospital Universitario Virgen de la Victoria

Malaga, , 29010

Site Contact

Site Contact

ricarda_g@yahoo.es

951032468

Pamplona, Spain

Status

Recruiting

Address

Clinica Universidad de Navarra, Dept of Oncology

Pamplona, , 31008

Site Contact

Site Contact

paurodriguez@unav.es

948-255-400

Hospital Universitario La Fe de Valencia, Valencia, Spain

Status

Recruiting

Address

Hospital Universitario La Fe de Valencia

Valencia, , 46026

Site Contact

Site Contact

delarubia_jav@gva.es

661028232

Inselspital Bern, Bern, Switzerland

Status

Not yet recruiting

Address

Inselspital Bern

Bern, , 3010

Lausanne, Switzerland

Status

Not yet recruiting

Address

Centre Hospitalier Universitaire Vaudois Lausanne (CHUV)

Lausanne, , 1011

Site Contact

Site Contact

holger.auner@chuv.ch

+1-877-825-3327

London, Greater London, United Kingdom

Status

Not yet recruiting

Address

Ambrose King Centre-Royal London Hospital-Barts Health NHS Trust

London, Greater London, E1 1BB

Site Contact

Site Contact

heather.oakervee@nhs.net

442078825958

Nottingham, Nottinghamshire, United Kingdom

Status

Not yet recruiting

Address

Nottingham University Hospitals NHS Trust - Nottingham City Hospital

Nottingham, Nottinghamshire, NG5 1PB

Site Contact

Site Contact

yan.hodgson@nuh.nhs.uk

115 9691169

London, United Kingdom

Status

Not yet recruiting

Address

Guy's Hospital - Guy's & St Thomas' NHS Foundation Trust

London, , SE1 9RT

Site Contact

Site Contact

matthew.streetly@gstt.nhs.uk

2071882756

London, United Kingdom

Status

Not yet recruiting

Address

Hammersmith Hospital - Imperial College Healthcare NHS Trust

London, , W12 0HS

Site Contact

Site Contact

aristeidis.chaidos@nhs.net

7913672624

Newcastle upon Tyne, United Kingdom

Status

Not yet recruiting

Address

Northern Centre for Cancer Care,The Newcastle Upon Tyne Hospitals NHS Foundation Trust

Newcastle upon Tyne, , NE7 7DN

Site Contact

Site Contact

andrew.charlton1@nhs.net

+1-877-825-3327